Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: Estimates based on indirect analysis using a systematic review and meta-regression analysis

European Psychiatry

Volumn 30, Issue 4, 2015, Pages 521-527

  Fridman, M ^a   Hodgkins, P S ^b,d   Kahle, J S ^c   Erder, M H ^b  

^a AMF Consulting   (United States)

^b SHIRE   (United States)

^c BPS International   (United States)

^d VERTEX PHARMACEUTICALS   (United States)

Author keywords

Attention deficit hyperactivity disorder (ADHD); Efficacy; Lisdexamfetamine; Psychiatry in Europe; Psychopharmacology others; Vyvanse

Indexed keywords

ATOMOXETINE; LISDEXAMFETAMINE; METHYLPHENIDATE; PLACEBO; CENTRAL STIMULANT AGENT; DOPAMINE UPTAKE INHIBITOR;

ADULT; ATTENTION DEFICIT DISORDER; CONFIDENCE INTERVAL; DRUG EFFICACY; EFFECT SIZE; EUROPEAN; HUMAN; PILL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; SENSITIVITY ANALYSIS; SHORT SURVEY; SYSTEMATIC REVIEW; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOSE RESPONSE; DRUG EFFECTS; EUROPE; FEMALE; FOLLOW UP; MALE; META ANALYSIS; TREATMENT OUTCOME;

ADULT; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LISDEXAMFETAMINE DIMESYLATE; MALE; METHYLPHENIDATE; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 84930867980     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2015.01.001     Document Type: Short Survey

References (40)

1. Adler L.A., Goodman D.W., Kollins S.H., Weisler R.H., Krishnan S., Zhang Y., et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008, 69(9):1364-1373.
2. Adler L.A., Zimmerman B., Starr H.L., Silber S., Palumbo J., Orman C., et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol 2009, 29(3):239-247.
3. Adler L.A., Spencer T., Brown T.E., Holdnack J., Saylor K., Schuh K., et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 2009, 29(1):44-50.
4. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2013, American Psychiatric Association, Arlington, VA. 5th ed.
5. Biederman J., Krishnan S., Zhang Y., McGough J.J., Findling R.L. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007, 29(3):450-463.
6. Biederman J., Mick E., Surman C., Doyle R., Hammerness P., Kotarski M., et al. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2010, 30(5):549-553.
7. Block S.L., Kelsey D., Coury D., Lewis D., Quintana H., Sutton V., et al. Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. Clin Pediatr (Phila) 2009, 48(7):723-733.
8. Brod M., Pohlman B., Lasser R., Hodgkins P. Comparison of the burden of illness for adults with ADHD across seven countries: a qualitative study. Health Qual Life Outcomes 2012, 10:47.
9. Casas M., Rosler M., Sandra Kooij J.J., Ginsberg Y., Ramos-Quiroga J.A., Heger S., et al. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. World J Biol Psychiatry 2013, 14(4):268-281.
10. Cochran W. The combination of estimates from different experiments. Biometrics 1954, 10:110-129.
11. Coghill D., Banaschewski T., Lecendreux M., Soutullo C., Johnson M., Zuddas A., et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol 2013, 23(10):1208-1218.
12. Cohen J. Statistical power analysis for the behavioral sciences 1988, L.Erlbaum Associates, Hillsdale, N.J., [xxi, 567p.]. 2nd ed.
13. Cunill R., Castells X., Tobias A., Capellà D. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression. Pharmacoepidemiol Drug Saf 2013, 22(9):961-969.
14. Dittmann R., Cardo E., Nagy P., Anderson C., Bloomfield R., Caballero B., et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs 2013, 27(12):1081-1092.
15. Durell T.M., Adler L.A., Williams D.W., Deldar A., McGough J.J., Glaser P.E., et al. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol 2013, 33(1):45-54.
16. Faraone S., Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010, 19(4):353-364.
17. Faraone S., Biederman J., Spencer T., Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed 2006, 8(4):4.
18. Findling R.L., Bukstein O.G., Melmed R.D., Lopez F.A., Sallee F.R., Arnold L.E., et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008, 69(1):149-159.
19. Findling R.L., Childress A.C., Cutler A.J., Gasior M., Hamdani M., Ferreira-Cornwell M.C., et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011, 50(4):395-405.
20. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0. Available from [updated March 2011]. http://www.cochrane-handbook.org.2011/.
21. Higgins J., Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
22. Kelsey D.K., Sumner C.R., Casat C.D., Coury D.L., Quintana H., Saylor K.E., et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004, 114(1):e1-e8.
23. Medori R., Ramos-Quiroga J.A., Casas M., Kooij J.J., Niemela A., Trott G.E., et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008, 63(10):981-989.
24. Michelson D., Faries D., Wernicke J., Kelsey D., Kendrick K., Sallee F.R., et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001, 108(5):E83.
25. Michelson D., Allen A.J., Busner J., Casat C., Dunn D., Kratochvil C., et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002, 159(11):1896-1901.
26. Michelson D., Adler L., Spencer T., Reimherr F.W., West S.A., Allen A.J., et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003, 53(2):112-120.
27. Montoya A., Hervas A., Cardo E., Artigas J., Mardomingo M.J., Alda J.A., et al. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin 2009, 25(11):2745-2754.
28. Newcorn J.H., Kratochvil C.J., Allen A.J., Casat C.D., Ruff D.D., Moore R.J., et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008, 165(6):721-730.
29. Polanczyk G., de Lima M.S., Horta B.L., Biederman J., Rohde L.A. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007, 164(6):942-948.
30. Polanczyk G., Willcutt E., Salum G., Kieling C., Rohde L. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol 2014, 43(2):434-442.
31. Sobanski E., Sabljic D., Alm B., Baehr C., Dittmann R.W., Skopp G., et al. A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD. Pharmacopsychiatry 2012, 45(3):100-107.
32. Spencer T., Heiligenstein J.H., Biederman J., Faries D.E., Kratochvil C.J., Conners C.K., et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002, 63(12):1140-1147.
33. Sutherland S.M., Adler L.A., Chen C., Smith M.D., Feltner D.E. An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD. J Clin Psychiatry 2012, 73(4):445-450.
34. Wehmeier P.M., Schacht A., Ulberstad F., Lehmann M., Schneider-Fresenius C., Lehmkuhl G., et al. Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology. J Clin Psychopharmacol 2012, 32(5):653-660.
35. Weisler R.H., Pandina G.J., Daly E.J., Cooper K., Gassmann-Mayer C. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs 2012, 26(5):421-434.
36. Wigal S.B., Kollins S.H., Childress A.C., Adeyi B. Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day. Child Adolesc Psychiatry Ment Health 2010, 4:32.
37. Wigal T., Brams M., Gasior M., Gao J., Giblin J. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Postgrad Med 2011, 123(2):169-176.
38. Wilens T.E., McBurnett K., Bukstein O., McGough J., Greenhill L., Lerner M., et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006, 160(1):82-90.
39. Wilens T.E., Gault L.M., Childress A., Kratochvil C.J., Bensman L., Hall C.M., et al. Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. J Am Acad Child Adolesc Psychiatry 2011, 50(1). 73-84 e1.
40. Young J.L., Sarkis E., Qiao M., Wietecha L. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2011, 34(2):51-60.